Eagle Pharmaceuticals (EGRX) 10-K 22 Dec 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document (USD $)	12 Months Ended
	Sep. 30, 2014	Dec. 17, 2014	Mar. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Eagle Pharmaceuticals, Inc.
Entity Central Index Key	827871
Current Fiscal Year End Date	-21
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		14,032,167
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$101,476,651

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$22,722	$10,456
Short-term investments	19,999	0
Accounts receivable	7,296	5,124
Inventories	1,294	0
Prepaid expenses and other current assets	1,711	1,903
Total current assets	53,022	17,483
Property and equipment, net	344	402
Other assets	45	46
Deferred initial public offering costs	0	172
Total assets	53,411	18,103
Current liabilities:
Accounts payable	4,059	1,192
Accrued expenses	9,671	3,130
Deferred revenue	6,585	10,020
Total current liabilities	20,315	14,342
Redeemable Series C Preferred Stock warrants	0	1,707
Shares subject to redemption:
Commitments and contingencies
Stockholders' Equity (Deficit):
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2014; no shares authorized, issued or outstanding as of September 30, 2013	0	0
Common stock, $0.001 par value; 50,000,000 and 80,000,000 shares authorized as of September 30, 2014 and 2013, respectively; 14,032,167 and 3,048,131 issued and outstanding as of September 30, 2014 and 2013, respectively	14	3
Additional paid in capital	137,259	14,204
Accumulated deficit	-104,177	-102,136
Total stockholders' equity (deficit)	33,096	-87,929
Total liabilities, shares subject to redemption and stockholders' equity (deficit)	53,411	18,103
Series A Convertible Preferred Stock
Shares subject to redemption:
Convertible preferred stock	0	20,057
Series B Convertible Preferred Stock
Shares subject to redemption:
Convertible preferred stock	0	30,090
Series B-1 Convertible Preferred Stock
Shares subject to redemption:
Convertible preferred stock	0	19,374
Series C Convertible Preferred Stock
Shares subject to redemption:
Convertible preferred stock	$0	$20,462

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Preferred Stock, Shares Authorized	1,500,000	0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, par value per share	$0.00	$0.00
Common stock, shares authorized	50,000,000	80,000,000
Common stock, shares, issued	14,032,167	3,048,131
Common stock, shares, outstanding	14,032,167	3,048,131
Series A Convertible Preferred Stock
Convertible preferred stock, par value per share	$0.00	$0.00
Convertible preferred stock, shares authorized	0	14,948,506
Convertible preferred stock, shares issued	0	14,948,506
Convertible preferred stock, shares outstanding	0	14,948,506
Series B Convertible Preferred Stock
Convertible preferred stock, par value per share	$0.00	$0.00
Convertible preferred stock, shares authorized	0	12,694,561
Convertible preferred stock, shares issued	0	12,694,561
Convertible preferred stock, shares outstanding	0	12,694,561
Series B-1 Convertible Preferred Stock
Convertible preferred stock, par value per share	$0.00	$0.00
Convertible preferred stock, shares authorized	0	9,331,374
Convertible preferred stock, shares issued	0	9,331,374
Convertible preferred stock, shares outstanding	0	9,331,374
Series C Convertible Preferred Stock
Convertible preferred stock, par value per share	$0.00	$0.00
Convertible preferred stock, shares authorized	0	11,901,336
Convertible preferred stock, shares issued	0	11,023,232
Convertible preferred stock, shares outstanding	0	11,023,232

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Revenue:
Product sales	$4,626	$5,315	$1,155
Royalty income	10,708	8,364	1,384
Other income	3,765	0	0
Total revenue	19,099	13,679	2,539
Operating expenses:
Cost of revenue	11,714	7,381	3,166
Research and development	16,816	9,795	12,805
Selling, general and administrative	9,326	4,958	6,399
Total operating expenses	37,856	22,134	22,370
Loss from operations	-18,757	-8,455	-19,831
Interest income	31	3	34
Net proceeds from arbitration	0	4,050	0
Interest expense	-8	-309	-91
Deferred financing costs	0	-96	-19
Amortization of debt discount	0	-1,091	-218
Loss on subscription loan settlement	0	0	-51
Change in value of warrant liability	-573	-1,052	0
Other income	35	3	12
Total other income/(expense)	-515	1,508	-333
Loss before income tax benefit	-19,272	-6,947	-20,164
Income tax benefit	1,295	899	781
Net Loss	-17,977	-6,048	-19,383
Less dividends on Series A, B, B-1 and C Convertible Preferred Stock	-1,666	-3,837	-3,933
Net loss attributable to common stockholders	($19,643)	($9,885)	($23,316)
Loss per share attributable to common stockholders Basic and diluted (in usd per share)	($1.97)	($3.25)	($14.11)
Weighted average common shares outstanding Basic and diluted	9,955,937	3,044,308	1,652,904

Condensed_Statements_of_Change

Condensed Statements of Changes in Stockholders' Equity (Deficit) Statement (USD $)	Total	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B-1 Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Preferred Stock Warrants	Common stock	Common stock	Common stock	Common stock	Common stock	Common stock	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified								Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B-1 Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Preferred Stock Warrants		Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B-1 Convertible Preferred Stock	Series C Convertible Preferred Stock	Series C Preferred Stock Warrants
Stockholders' equity attributable to parent, beginning balance at Sep. 30, 2011	($71,174)						$2						$1,045						($72,221)
Number of Shares outstanding, beginning balance at Sep. 30, 2011							1,701,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	402												402
Beneficial conversion value of notes payable	655												655
Forfeitures of stock, (in shares)							-48,000
Forfeitures of stock, value							0						0
Net loss	-19,383																		-19,383
Dividends on Convertible Preferred Stock	-3,933																		-3,933
Stockholders' equity attributable to parent, ending balance at Sep. 30, 2012	-93,433						2						2,102						-95,537
Number of shares outstanding, ending balance at Sep. 30, 2012							1,653,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	317												317
Conversion of preferred shares to common stock, (in shares)								825,000	524,000	46,000
Conversion of preferred shares to common stock, value		5,136	6,111	539				1	0	0				5,135	6,111	539
Net loss	-6,048																		-6,048
Dividends on Convertible Preferred Stock	-3,837																		-3,837
Forfeitures of dividends on Convertible Preferred Stock																			3,286
Stockholders' equity attributable to parent, ending balance at Sep. 30, 2013	-87,929						3						14,204						-102,136
Number of Shares outstanding, beginning balance at Sep. 30, 2013							3,048,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	606												606
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount	3,450,000
Issuance of common stock in connection with initial public offering, including underwriter's over-allotment, net of offering costs and underwriter's discount	46,048						3						46,045
Conversion of preferred shares to common stock, (in shares)								2,332,000	1,980,000	1,456,000	1,720,000	32,000
Conversion of preferred shares to common stock, value		20,377	30,612	19,756	20,903	2,280		3	2	1	2	0		20,374	30,610	19,755	20,901	2,280
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants (in shares)							2,000
Issuance of common stock upon exercise of Redeemable Series C Preferred Stock warrants	21						0						21
Issuance of common stock upon exercise of stock option grants (in shares)							12,000
Issuance of common stock upon exercise of stock option grants	65						0						65
Dividends on Convertible Preferred Stock and forfeitures of dividends on conversion to common	0												-17,602						17,602
Net loss	-17,977
Dividends on Convertible Preferred Stock	-1,666																		-1,666
Stockholders' equity attributable to parent, ending balance at Sep. 30, 2014	$33,096						$14						$137,259						($104,177)
Number of shares outstanding, ending balance at Sep. 30, 2014							14,032,000

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	($17,977)	($6,048)	($19,383)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	104	135	240
Stock-based compensation	606	317	402
Non-cash interest expense	0	309	90
Amortization of deferred financing costs	0	96	19
Amortization of debt discount	0	1,091	218
Change in fair value of warrant liability	573	1,052	0
Loss on subscription loan settlement	0	0	51
Changes in operating assets and liabilities:
(Increase) in accounts receivable	-2,172	-3,543	-1,320
(Increase) decrease in inventories	-1,294	87	1,052
Decrease (increase) in prepaid expenses and other current assets	192	-1,368	197
Decrease in other assets	1	30	0
Increase (decrease) in accounts payable	2,867	-251	-93
(Decrease) increase in deferred revenue	-3,435	520	3,500
Increase (decrease) in accrued expenses and other liabilities	6,692	1,694	-521
Net cash used in operating activities	-13,843	-5,879	-15,548
Cash flows from investing activities:
Purchase of property and equipment	-46	-41	-33
(Purchase) proceeds from/of short term investments	-19,999	1,500	3,000
Net cash (used in) provided by investing activities	-20,045	1,459	2,967
Cash flows from financing activities:
Proceeds from Convertible Notes and Warrants	0	0	9,663
Proceeds from issuance of Series C preferred stock, net of offering costs of $160	0	9,829	0
Deferred financing costs	0	0	-115
Deferred IPO costs	0	-20	0
Series C preferred stock offering costs	-1	0	0
Proceeds from exercise of preferred stock warrants	21	0	0
Proceeds from issuance of common stock from initial public offering, net of issuance costs	46,069	0	0
Proceeds from common stock option exercise	65	0	0
Net cash provided by financing activities	46,154	9,809	9,548
Net increase (decrease) in cash	12,266	5,389	-3,033
Cash and cash equivalents at beginning of period	10,456	5,067	8,100
Cash and cash equivalents at end of period	22,722	10,456	5,067
Cash paid during the period for:
Interest		0	0
Financing costs	0	20	0
Interest Expense	8	309	91
Franchise taxes	9	20	20
Non-Cash Financing Activities [Abstract]
Fair value of warrants issued with notes payable and the beneficial conversion feature	0	0	1,309
Conversion of note payable to Preferred Stock	0	10,062	0
Accrued IPO costs	0	152	0
Conversion of Preferred Stock and Accrued Dividends to Common Stock
Non-Cash Financing Activities [Abstract]
Conversion to Common Stock	91,648	15,623	3,933
Conversion of Redeemable Warrant Liability to Common Stock
Non-Cash Financing Activities [Abstract]
Conversion to Common Stock	$2,280	$0	$0

Condensed_Statements_of_Cash_F1

Condensed Statements of Cash Flows Parenthetical (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Net offering costs	$0
Series C Preferred Stock [Member]
Net offering costs	($159,727)

Organization_and_Business_Acti

Organization and Business Activities	12 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Activities	Organization and Business Activities
	Eagle Pharmaceuticals, Inc. (the Company, or Eagle) is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the FDA's 505(b)(2) NDA regulatory pathway. The Company's business model is to develop proprietary innovations to FDA-approved, injectable drugs, referred to as branded reference drugs, that offer favorable attributes to patients and healthcare providers. The Company has two products currently being sold in the United States, Ryanodex®, launched in August 2014, and a ready-to-use formulation of argatroban under various license agreements in place with commercial partners. The Company has a number of products currently under development and certain products may be subject to license agreements.
	On February 18, 2014, the Company closed its initial public offering whereby the Company sold 3,350,000 shares of common stock, at a public offering price of $15.00 per share, before underwriting discounts and expenses. On March 18, 2014, the underwriters exercised an over-allotment option granted in connection with the offering of 100,000 shares of common stock at the initial public offering price, less the underwriter discount. The aggregate net proceeds received by the Company from the offering were $46,069. Included in this amount is $21 received from the exercise of Series C preferred stock warrants for 1,788 shares of common stock.
	In connection with the initial public offering, the Company's Board of Directors approved a one-for-6.41 reverse stock split of the Company's common stock (that resulted in a proportional adjustment to the conversion ratio of the preferred stock warrants). All references to common stock, common stock equivalents and per share amounts have been changed retroactively in these condensed financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital.
	On the initial public offering date, all outstanding shares of preferred stock converted into 7,487,928 shares of common stock and the outstanding warrants were net exercised for 32,286 shares common stock at the initial public offering price. These transactions produced a significant increase in the number of shares outstanding which will impact the year-over-year comparability of the Company’s (loss) earnings per share calculations. Additionally, in connection with the closing of the IPO, the Company amended and restated its articles of incorporation to decrease the number of authorized shares of common and undesignated preferred stock to 50,000,000 and 1,500,000, respectively.
	These financial statements are presented in U.S. dollars and are prepared under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
	Accounting Guidance Not Yet Adopted
	In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and have not yet determined the method by which we will adopt the standard in 2017.
	Reclassifications
	Certain reclassifications have been made to prior year amounts to conform with the current year presentation.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
	The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.
	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash and cash equivalents, accounts receivable, and accounts payable. The carrying values of these financial instruments approximate their fair values due to their short term maturities.
	Short Term Investments
	Investments consisted of U.S. Treasury securities that had an original maturity of greater than three months. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
	Fair Value Measurements
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	•	Level 1: Quoted prices in active markets for identical assets or liabilities.
	•	Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The fair value of interest-bearing cash and cash equivalents and short term investments are classified as Level 1 at September 30, 2014 and September 30, 2013.
	The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis.
	The guidance in ASC 815 required that the Company mark the value of its warrant liability (See Note 6) to market and recognize the change in valuation in its statement of operations each reporting period. Determining the warrant liability to be recorded required the Company to develop estimates to be used in calculating the fair value of the warrant.
	Since these preferred stock warrants did not trade in an active securities market, the Company recognized a warrant liability and estimated the fair value of these warrants using a Probability-Weighted Expected Returns valuation model. Therefore, the warrant liability was considered a Level 3 measurement. All warrants outstanding immediately prior to the public offering were net exercised in connection with the initial public offering. There were no outstanding warrants as of September 30, 2014.
	Concentration of Major Customers and Vendors
	The Company is dependent on commercial partners to market and sell argatroban, from which most of its revenues are currently derived; therefore, the Company's future revenues are highly dependent on these distribution arrangements.
	Total Product Sales and Royalty revenues, and accounts receivables broken down by major customers as a percentage of the total are as follows:
		Year Ended September 30,
		2014			2013		2012
	Net product sales and royalty revenues
	The Medicines Company	45	%		54	%	100	%
	Sandoz, Inc.	53	%		46	%	0	%
	Other	2	%		0	%	0	%
		100	%		100	%	100	%
		September 30,
		2014			2013
	Accounts receivable
	The Medicines Company	75	%		58	%
	Sandoz, Inc.	18	%		40	%
	Other	7	%		2	%
		100	%		100	%
	Currently, for argatroban, the Company uses one vendor as its sole source of supplier. Because of the unique equipment and process for manufacturing argatroban, transferring manufacturing activities for argatroban to an alternate supplier would be a time- consuming and costly endeavor, and there are only a limited number of manufacturers that are capable of performing this function for the Company.
	Pre-Launch Inventory
	The Company capitalizes inventory costs associated with certain products prior to regulatory approval and product launch, based on management's judgment of reasonably certain future commercial use and net realizable value, when it is reasonably certain that the pre-launch inventories will be saleable. The determination to capitalize is made once the Company (or its third party development partners) has filed a New Drug Application (an "NDA") that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal hurdles will be cleared. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the drug product being considered, and accordingly, the time frame within which the determination is made varies from product to product. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, or a delay in commercialization, or other potential factors. The Company did not have pre-launch inventory as of September 30, 2014 and 2013.
	Inventory
	Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis and consists of finished products. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers.
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term.
	Research and Development Expense
	Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or services performed.
	Deferred Financing Costs
	Prior to the initial public offering, costs relating to obtaining Convertible Notes were capitalized and amortized over the term of the related debt using the straight line method. Amortization of deferred financing costs charged to interest expense was $0, $96 and $19 for the years ended September 30, 2014, 2013, and 2012, respectively. The unamortized balance as of September 30, 2014 and September 30, 2013 was $0.
	Deferred Initial Public Offering Costs
	Costs incurred of $2,074 related to the initial public offering, consisting primarily of professional fees, were deferred until the completion of the offering at which time such costs, as well as underwriters' fees paid, were netted against proceeds received and reclassified to Additional paid-in capital.
	Advertising and Marketing
	Advertising and marketing costs are expensed as incurred. Advertising and marketing costs were $2,506 for the year ended September 30, 2014 and immaterial for the years ended September 30, 2013 and September 30, 2012.
	Redeemable Convertible Preferred Stock
	The carrying value of redeemable convertible preferred stock was increased by periodic accretions, using the interest method so that the carrying amount would equal the redemption amount at the earliest redemption date.
	Accounting for Income Taxes
	The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.
	Revenue Recognition
	Product Revenue — The Company recognizes net revenue from Argatroban supplied to its commercial partners and Ryanodex® supplied to the end user, when the following four basic revenue recognition criteria under the related accounting guidance are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with cGMP. The Company's commercial partners can return the products within contracted specified timeframes if the products do not meet the applicable inspection tests.The Company estimates its return reserves based on its experience with historical return rates. Historically, product returns have not been material. The Company has a no return policy for Ryanodex®.
	Revenues from product sales to end users are recorded net of provisions for estimated chargebacks, rebates, returns (if applicable), prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Eagle, the revenue is deferred to a future period when more information is available to evaluate the impact.
	Royalties — The Company recognizes revenue from royalties based on its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial.
Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as the well as research and development performed by outside contractors or consultants.
The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the collaboration agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the upfront license fee is recognized accordingly on a prospective basis. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement. No such revenue was recorded in years ended September 30, 2014, 2013 and 2012.
See Note 11 regarding Asset Sales related to Other Income of $3,500 recognized in June 2014.
Stock-Based Compensation
The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors. The Company uses a Black-Scholes valuation model as the most appropriate valuation method for pricing these options. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock.
The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions:
	Year Ended September 30,
	2014		2013		2012
Risk-free interest rate	1.77% - 2.16%		.95% - 2.53%		.82% - 3.23%
Volatility	53.7%-64.0%		64.00%		34.34%-39.38%
Expected term (in years)	6.07 - 9.39 years		6.07 - 10.00 years		6.07 - 10.00 years
Expected dividend yield	0.00%		0.00%		0.00%
The risk-free rate assumption was based on U.S. Treasury instruments whose term was consistent with the expected term of the stock options. The expected stock price volatility was determined by examining the historical volatilities for industry peers as the Company did not have any trading history for its common stock. Industry peers consist of those companies in the pharmaceutical industry similar in size, stage of life-cycle and financial leverage. The expected term of stock options represents the average of the vesting period and the contractual life of the option for employees and the life of the option for consultants. The expected dividend assumption is based on the Company's history and expectation of future dividend payouts. Changes in the estimated forfeiture rates are reflected prospectively.
Net Loss Per Share
Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. Since the Company has incurred net losses for all periods, basic loss per share and diluted loss per share are the same.
The anti-dilutive common shares equivalents outstanding at the years ended September 30, 2014, 2013 and 2012 were as follows:
	Year Ended September 30,
	2014			2013		2012
Series A	888,099			2,332,059		3,157,154
Series B	754,191			1,980,429		2,504,197
Series B-1	554,382			1,455,750		1,501,930
Series C	654,896			1,719,690		—
Series C warrants	56,078			147,254		30,971
Options	963,495			813,529		739,808
Total	3,871,141			8,448,711		7,934,060

Inventories

Inventories	12 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consist of the following:
		September 30,
		2014		2013
	Finished products	$	1,294	$	—
		$	1,294	$	—

Property_and_Equipment

Property and Equipment	12 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure	Property and Equipment
	Property and equipment at consist of the following:
		September 30,						Estimated Useful Life (years)
		2014			2013
	Furniture and equipment	$	297		$	297		7
	Office equipment	193			293			3
	Equipment	593			593			7
	Leasehold improvements	41			41			2
		1,124			1,224
	Less accumulated depreciation	(780		)	(822		)
	Property and equipment, net	$	344		$	402
	Depreciation expense amounted to $104, $135, and $240 for the years ended September 30, 2014, 2013 and 2012, respectively.
	Included in equipment are assets held for future use which are not subject to depreciation. As of September 30, 2014, and 2013 this equipment amounted to approximately $270.

Balance_Sheet_Accounts

Balance Sheet Accounts	12 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts
	Prepaid and Other Current Assets
	Prepaid and other current assets consist of the following:
		September 30,
		2014		2013
	Prepaid expenses and other current assets
	Prepaid product costs	$	840	$	730
	Prepaid FDA user fee	197		1,023
	Prepaid insurance	345		118
	All other	329		32
	Total Prepaid expenses and other current assets	$	1,711	$	1,903
	Accrued Expenses
	Accrued expenses consist of the following:
		September 30,
		2014		2013
	Accrued expenses
	Royalties due to The Medicines Company	$	4,707	$	1,724
	Royalties due to SciDose	1,050		547
	Accrued research & development	1,498		283
	Accrued professional fees	591		275
	Accrued salary and other compensation	890		170
	Accrued product costs	490		63
	All other	445		68
	Total Accrued expenses	$	9,671	$	3,130
	Deferred Revenue
	Deferred revenue consists of the following:
		September 30,
		2014		2013
	Deferred revenue
	The Medicines Company	$	585	$	520
	Deferred Revenue for ongoing business	585		520
	Hikma Pharmaceuticals, Co. Ltd. (See Note 11)	—		3,500
	Par Pharmaceuticals Companies, Inc.	5,500		5,500
	Par Pharmaceuticals Companies, Inc./Tech Transfer	500		500
	Deferred Revenue from Asset Sales (See Note 11)	6,000		9,500
	Total Deferred revenue	$	6,585	$	10,020

Notes_Payable

Notes Payable	12 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Notes Payable	Notes Payable
	Convertible Notes
	The Company entered into a Convertible Note and Warrant Purchase Agreement (the "Convertible Note Agreements"), pursuant to which it issued $9,663 of Convertible Notes (the "Convertible Notes") to existing preferred stockholders. The loan funding was completed in two tranches on August 2, 2012 and September 26, 2012, respectively. Holders of the Convertible Notes were entitled to cumulative interest at an annual rate of 6%. Such interest accrued daily and was cumulative from the respective date. In addition, the holders received warrants to purchase preferred stock, which accrued at a monthly rate of 2% of the principal amount until the completion of a Qualified Financing, as defined in the Convertible Note Agreement, or August 1, 2013, whichever was sooner.
	The Convertible Notes and associated accrued interest were due and payable on August 1, 2013, unless the Convertible Notes converted earlier. Conversion could occur, upon certain triggering events or the holder elects to convert. Principal and interest accrued shall convert into shares of preferred stock: a) upon the attainment of a Qualified Financing, or b) on August 1, 2013, whichever is sooner. Upon conversion pursuant to (a), the aggregate amount converted will be divided by the offering price of the Qualified Financing to arrive at the amount of preferred stock that will be issued. Upon conversion pursuant to (b), the aggregate amount converted will be divided by $1.82 to arrive at the amount of preferred stock that will be issued.
	The Series C Preferred Share financing (See Note 7) represented a Qualified Financing whereby the Convertible Notes for those participating investors converted to Series C Preferred Shares.
	The Convertible Notes agreement was structured such that a portion of the shares of the Company's Series A preferred stock, Series B preferred stock and Series B-1 preferred stock, collectively the "Special Conversion Preferred", held by a holder, that did not participate in the financing to the full extent of its pro-rata share of preferred stock ownership (a "Non-Fully Participating Holder"), was converted into shares of the Company's Common Stock, and any dividends accumulated to date were forfeited.
	The option for existing preferred stockholders to participate in the Convertible Notes expired on October 1, 2012. On October 2, 2012, 8,943,447 shares of preferred stock held by Non-Fully Participating Holders were converted into 1,395,226 shares of Common Stock.
	Warrants
	Prior to the initial public offering, the Company accounted for the warrants as liability instruments. The Company estimated the initial fair value of the 944,210 warrants to be $655 using a Probability-Weighted Expected Returns valuation model. At each reporting period, any changes to the fair value of the warrants were recorded in the statements of operations. As of September 30, 2014 and September 30, 2013, warrants to purchase 0 and 944,210 shares of common stock, respectively, were outstanding in connection with the warrants.
	The valuation model considered three scenarios. Two of the scenarios assumed a stockholder exit, either through sale, or dissolution. The third scenario assumed operations continue as a private company and no exit transaction occurred. The following assumptions were used in the valuation: exercise price of $1.82; implied stock price of $1.82; expected volatility of 64%; expected dividend rate of 6%; risk free interest rate of 0.83% and expiration date of six years.
	The following was a description of the key terms of the warrants per the warrant purchase agreement:
	•	Exercise period — Exercisable, in whole or in part, during the six year term commencing on the earliest to occur of: (a) the consummation of a Qualified Financing, (b) immediately prior to the consummation of a Change of Control (but subject to and contingent upon such consummation of a Change of Control) and (c) the date one year after the Initial Closing or August 1, 2013.
	•	Exercise Price — The purchase price for the Warrant Shares issuable was: (a) $1.82, or (b) the offering price of a Qualified Financing should this occur prior to August 1, 2013.
	•	No Rights as Stockholders — Prior to the exercise of the warrants, no holder of warrants (solely in its capacity as a holder of warrants) is entitled to any rights as a stockholder of the Company, including, without limitation, the right to vote, receive notice of any meeting of stockholders or receive dividends, allotments or other distributions.
	In February 2014, proceeds in the amount of $21 were received from the exercise of Series C preferred stock warrants for 1,788 common shares. In addition, Redeemable Series C preferred stock warrants were net exercised for 32,286 shares common stock upon the closing of the initial public offering.
	Warrant Liability
	On February 18, 2014, the initial public offering date, the estimated fair value of the Convertible Note warrant liability was $2,280 which resulted in a charge to other income and expense of $383. The change in the value of the warrant liability was $573, $1,052 and $0 for the years ended September 30, 2014, 2013 and 2012, respectively. As of September 30, 2013, the estimated fair value of the Convertible Note warrant liability was $1,707 which resulted in a charge to other income and expense of $1,052 for the year ended September 30, 2013. Upon the completion of the qualified offering, the warrants became exercisable into Series C Preferred Shares. The increase in the fair value of the warrant liability is primarily attributable to the liquidation preference of the Series C Preferred Shares to receive 2 times the original investment upon a liquidation event under certain circumstances.
	Debt Discount
	In connection with the Convertible Notes described above and as a result of the warrants issued with the Convertible Notes, the Company determined that a discount to the debt should be recorded in the amount of $655, representing its fair value and recorded as a discount to the debt instrument and amortized over the life of the instrument. The amount recorded as interest expense during the years ended September 30, 2014, 2013 and 2012 was $0, $545 and $109, respectively. Due to the conversion of the Convertible Notes to preferred stock, the balance of the unamortized debt discount was written off during the year ended September 30, 2013, resulting in interest expense of $545.
	Beneficial Conversion Feature
	A convertible financial instrument includes a beneficial conversion feature if the effective conversion price is less than the Company's market price of preferred stock on the commitment date. The effective price paid for a share is the amount allocated to the convertible instrument, divided by the number of shares the holder is entitled to upon conversion. If the convertible financial instrument is issued with warrants and/or other detachable instruments, the amount allocated to the convertible instrument is the face amount less the allocation to the detachable instruments.
	In connection with the Convertible Notes described above and as a result of the warrants issued with the Convertible Notes, the Company determined that the conversion rate represented a beneficial conversion feature. Accordingly, a discount on the notes was recorded in the amount of $655. The discount was amortized ratably with a corresponding non-cash charge to interest expense. The amount recorded as interest expense during the years ended September 30, 2014, 2013 and 2012 was approximately $0, $545 and $109, respectively. Due to the conversion of the Convertible Notes to preferred stock, the balance of the unamortized beneficial conversion feature was written off during the year ended September 30, 2013, resulting in interest expense of $545.

Shares_Subject_to_Redemption_C

Shares Subject to Redemption b Convertible Preferred Stock	12 Months Ended
	Sep. 30, 2014
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount [Abstract]
Shares Subject to Redemption - Convertible Preferred Stock	Shares Subject to Redemption — Convertible Preferred Stock
	Series A Convertible preferred stock
	On March 8, 2007, the Company issued 20,237,911 shares of Series A Convertible preferred stock, par value $0.001 (the "Series A preferred stock"). The outstanding shares of the Series A preferred stock (as amended in connection with the issuance of the Series B preferred stock) is redeemable after August 11, 2013 at a redemption price per share equal to the Original Issue Price of $0.971 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding Series A convertible preferred stock converted into 2,332,051 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series A preferred stock were recorded at their estimated fair value of $19,651 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $180. The fair value of the Series A preferred stock had been increased through periodic accretions using the interest method for dividends (see "Preferred Stock Dividends" below) so that the carrying value equals the redemption amount on the redemption date. Accumulated dividends on the Series A preferred stock as of September 30, 2014 and September 30, 2013 were $0 and $5,722 respectively. The liquidation value of the Series A preferred stock was $0 and $20,237 as of September 30, 2014 and September 30, 2013, respectively. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 of the Series A preferred stock was $97.
	Series B Convertible Preferred Stock
	On August 11, 2008, the Company issued 16,052,343 shares of Series B Convertible preferred stock, par value $0.001 (the "Series B preferred stock"). The Series B preferred stock is redeemable as described above for the Series A preferred stock at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding Series B convertible preferred stock converted into 1,980,431 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series B preferred stock were recorded at their estimated fair value of $29,215, which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $126. The fair value of the Series B preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. Accumulated dividends on redeemable shares as of September 30, 2014, and September 30, 2013 were $0 and $7,111, respectively. The liquidation value of the Series B preferred stock is $0 and $30,216 as of September 30, 2014 and September 30, 2013, respectively. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 was $173.
	Series B-1 Convertible Preferred Stock
	The Company consummated an offering of Series B-1 Convertible preferred stock, par value $0.001 (the "Series B-1 Preferred Stock") to its existing investors in two stages in February 2011 and July 2011. The Company issued an aggregate of 10,177,085 shares of Series B-1 preferred stock. The Series B-1 preferred stock is redeemable at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding series B-1 convertible preferred stock converted into 1,455,753 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series B-1 preferred stock were recorded at their estimated fair value of $17,522 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $144. On August 2, 2012, the Company entered into a Payoff and Exchange Agreement with an Officer/Director. The Company accepted a total of 549,451 shares of Series B-1 preferred stock in exchange for satisfaction of the principal amount of debt. The total number of outstanding shares of Series B-1 preferred stock was 9,627,634 as of September 30, 2012. The fair value of the Series B preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. Accumulated dividends on redeemable shares were $0 and $2,535 as of September 30, 2014 and September 30, 2013, respectively. The liquidation value of the Series B-1 preferred stock is $0 and $19,519 as of September 30, 2014 and September 30, 2013, respectively. The accumulated dividend through the closing date of the initial public offering on February 18, 2014 of the Series B-1 preferred stock was $125.
	Series C Convertible Preferred Stock
	The Company consummated an offering of Series C Convertible preferred stock, par value $0.001 (the "Series C preferred stock") on April 11, 2013. The Company issued an aggregate of 11,023,232 shares of Series C preferred stock. The Series C preferred stock is redeemable at a redemption price per share equal to the Original Issue Price of $1.82 per share plus accrued but unpaid dividends (see "Redemption" below). The outstanding series C convertible preferred stock converted into 1,719,693 shares of common stock upon the closing of the initial public offering. The outstanding shares of the Series C preferred stock were recorded at their estimated fair value of $20,062 which equaled the sale price on the date of issuance. The amount was adjusted for net offering costs of $167. The fair value of the Series C preferred stock had been increased through periodic accretions using the interest method so that the carrying value equals the redemption amount on the redemption date. Accumulated dividends on redeemable shares were $0 and $567 as of September 30, 2014 and September 30, 2013, respectively. The liquidation value of the Series C preferred stock is $0 and $20,630 as of September 30, 2014 and September 30, 2013, respectively. The accumulated dividend through closing date of the initial public offering on February 18, 2014 of the Series C preferred stock was $139.
	On October 2, 2012, holders of preferred stock who elected not to participate in the Convertible Notes (see "Notes Payable") had their preferred stock shares convert to Common stock. Upon conversion from preferred to common, the investors forfeited all accumulated dividends from their investment date and 5,289,405 shares of Series A preferred stock were converted into 825,177 shares of Common stock and $1,718 in accumulated dividends was forfeited, 3,357,782 shares of Series B preferred stock were converted into 532,832 shares of Common Stock and $1,520 in accumulated dividends was forfeited, and 296,260 shares of Series B-1 preferred stock were converted into 46,218 shares of Common stock and $49 in accumulated dividends was forfeited. Concurrent with the conversion, the Company reduced the amounts authorized for the Series A, Series B, and Series B-1 preferred stock to 14,948,506 shares, 12,694,561 shares and 9,331,374 shares, respectively.
	Preferred Stock Dividends
	Holders of Series A, Series B, Series B-1 and Series C Preferred Stockholders were entitled to cumulative dividends at an annual rate of 6% when and if declared. Such dividends accrued daily on a cumulative basis from the respective date of issuance of each such share of Preferred Stock, whether declared or not.
	Dividends were to be paid only when declared by the Board of Directors out of legally available funds or upon the first to occur of (i) payment of the Original Issue Price of each share of Preferred Stock in connection with a redemption or liquidation event or (ii) upon conversion of the Preferred Stock into Common Stock, unless the conversion was done in connection with a Qualified IPO or the sale of the Company under certain conditions ("Qualified Sale"), which would have caused the holder to forfeit such dividends.
	No dividends had been declared as of or for any period. Accumulated dividends had accrued for Series A, Series B, Series B-1 and Series C Preferred Stock as follows and converted to Common Stock at the IPO:
		September 30,
		2014		2013		2012
	Series A	—		5,722		6,564
	Series B	—		7,111		7,252
	Series B-1	—		2,535		1,569
	Series C	—		567		—
	Total	$	—	$	15,935	$	15,385

Common_Stock_and_StockBased_Co

Common Stock and Stock-Based Compensation	12 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock and Stock-Based Compensation	Common Stock and Stock-Based Compensation
	In December 2007, the Company's Board of Directors approved the 2007 Incentive Compensation Plan (the "2007 Plan") enabling the Company to grant multiple stock based awards to employees, directors and consultants, the most common being stock options and restricted stock awards. In November 2013, the Company's Board of Directors approved the 2014 Equity Incentive Plan (the "2014 Plan") which became effective on February 11, 2014. The 2007 Plan was terminated upon the effectiveness of the 2014 Plan and all shares available for issuance under the 2007 Plan were made available under the 2014 Plan. The 2014 Plan provides for the awards of incentive stock options, non-qualified stock options, restricted stock, restricted stock units and other stock-based awards. Awards generally vest equally over a period of four years from grant date. Vesting is accelerated under a change in control of the Company or in the event of death or disability to the recipient. In the event of termination, any unvested shares or options are forfeited. The Company has reserved and made available 974,311 shares of common stock for issuance under the 2014 Plan.
	The Company recognized share-based compensation in its statements of operations for the years ended September 30, 2014, 2013 and 2012 as follows:
		Year Ended September 30,
		2014			2013			2012
	Selling, general and administrative	$	303		$	153		$	281
	Research and development	303			164			121
	Total	$	606		$	317		$	402
	The following table is a summary of the Company's stock options issued to employees, directors and consultants (amounts in thousands except per share amounts):
		Number of		Weighted			Non-			Exercisable
		Stock		Average			Exercisable
		Option		Exercise
		Shares		Price
	Outstanding at September 30, 2011	657,850		$	5.32		288,605			369,245
	Granted	195,471		$	8.78
	Exercised	—
	Forfeited or expired	(113,513	)
	Outstanding at September 30, 2012	739,808		$	6.22		304,226			435,582
	Granted	194,065		4.42
	Exercised	—
	Forfeited or expired	(120,614	)
	Outstanding at September 30, 2013	813,259		$	5.58		302,603			510,656
	Granted	558,699		11.72
	Exercised	(12,034	)	$	5.34
	Forfeited or expired	(50,931	)
	Outstanding at September 30, 2014	1,308,993		$	8.16		712,901			596,092
	The weighted-average grant-date fair value of options granted during the years ended September 30, 2014, 2013 and 2012 was $4.61, $1.73 and $3.40, respectively. As of September 30, 2014, there was $2,614 of unrecognized compensation cost, which will be expensed over the next 4 fiscal years. The total intrinsic value of options exercised during the year ended September 30, 2014 was $83. There were no options exercised during the year ended September 30, 2013.
	The weighted average contractual terms of options outstanding as of September 30, 2014, 2013 and 2012 was 7.5, 7.0 and 7.5 years, respectively.
	The aggregate pre-tax intrinsic value of options outstanding as of September 30, 2014, 2013 and 2012 was $5,880, $179 and $1,845, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure	Income Taxes
	The benefit for income taxes shown in the statement of operations is net of $3, $2 and $2 for minimum state taxes for the years ended September 30, 2014, 2013, and 2012, respectively.
	A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:
		Year Ended September 30,
		2014			2013			2012
	Federal tax benefit at statutory rate	(34.00	)%		(34.00	)%		(34.00	)%
	Non-cash interest and change in fair value of warrants liability	1.07	%		13.82	%		—	%
	State tax benefit, net of Federal benefits	(6.72	)%		(12.95	)%		(3.88	)%
	Research & Development Credit	0.62	%		(5.14	)%		(0.72	)%
	Other	0.06	%		0.22	%		0.07	%
	Net changes in valuation allowance	32.25	%		25.11	%		34.65	%
	Tax benefit	(6.72	)%		(12.94	)%		(3.88	)%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets were as follows:
		September 30,
		2014				2013
	Deferred tax assets
	Net operating loss carryforward	$	32,527			$	26,984
	Prepaid research & development expenses	2,354				2,573
	Research & development credit	1,886				2,033
	Advance billings	234				208
	Stock based compensation	944				688
	Accrued bonus	204				—
	Patent costs	70				77
	Intangible assets	34				39
	Fixed assets	—				161
	Accrued vacation pay	54				—
	Returns and allowances	—				24
	Charitable contribution carryforward	80				28
	Other	2				2
	Total deferred tax assets	38,389				32,817
	Deferred tax liabilities
	Prepaid expenses	138				47
	Fixed assets	5				—
	Total deferred tax liabilities	143				47
	Net deferred tax assets	38,246				32,770
	Valuation allowance	$	(38,246	)		$	(32,770	)
	Realization of the net deferred tax asset is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax asset has been offset by a full valuation allowance. The valuation allowance increased by $(5,476) as of September 30, 2014.
	As of September 30, 2014, the Company had federal and state net operating loss carryforwards of approximately $90,448 and $29,881, respectively. As of September 30, 2014, the Company also had a federal and state research and development tax credit carryforwards of approximately $1,827 and $59, respectively. These net operating loss carryforwards and credits expire at various times from 2015-2034.
	Section 382 of the Internal Revenue Code generally requires a corporation to limit the amount of its income in future years that can be offset by historic losses, i.e. net operating loss (NOL) carryforwards and certain built-in losses, after a corporation has undergone an ownership change. The Company has not been subject to a Section 382 limitation.
	In July 2006, the Financial Accounting Standards Board (“FASB”) issued ASC 740-10, Uncertainty in Income Taxes, which defines the threshold for recognizing the benefits of tax-return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities. This statement also requires explicit disclosure requirements about a Company’s uncertainties related to their income tax position, including a detailed roll-forward of tax benefits taken that do not qualify for financial statement recognition. There are no such amounts recorded due to the adoption of the tax standard.
	The Company files income tax returns in the U.S. federal jurisdiction and New Jersey. Given that the company has incurred tax losses since its inception, all of the Company’s tax years are effectively open to examination. The Company has no amount recorded for any unrecognized tax benefits as of September 30, 2014 nor did the Company record any amount for the implementation of ASC 740-10-25. The Company regularly evaluates its tax positions for additional unrecognized tax benefits and associated interest and penalties, if applicable. The Company believes that its accrual for tax liabilities is adequate for all open years. There are many factors that are considered when evaluating these tax positions including: interpretation of tax laws, recent tax litigation on a position, past audit or examination history, and subjective estimates and assumptions. In making these estimates and assumptions, the Company relies on advice from industry and subject matter experts, analyzes actions taken by taxing authorities, as well as the Company’s industry and audit experience. These evaluations are based on estimates and assumptions that have been deemed reasonable by management. However, if management’s estimates are not representative of actual outcomes, the Company’s results could be materially impacted.
	The Company received approval to sell a portion of the Company's New Jersey net operating losses ("NOL's") as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology firms with unused net operating loss carryovers and unused research and development credits are allowed to sell these benefits to other firms.
	During the year ended September 30, 2014, the Company sold New Jersey state net operating loss (NJ NOL) carry forwards and tax credits totaling $25,389 and $177, respectively for net proceeds of $1,295 which is reflected as a tax benefit in fiscal year 2014. In fiscal year ended September 30, 2013, the Company sold net operating losses and tax credits totaling $11,029 and $95, respectively for net proceeds of $899 which is reflected as a tax benefit in fiscal year 2013. In fiscal year 2012, the Company sold net operating losses totaling $10,740 and $11, respectively for net proceeds of $781 which is reflected as a tax benefit in fiscal 2012.

License_Agreements_of_Developm

License Agreements of Development and Commercialization Rights	12 Months Ended
	Sep. 30, 2014
Research and Development [Abstract]
License Agreements of Development and Commercialization Rights	License Agreements of Development and Commercialization Rights
	Development
	The Company has entered into several product development agreements with development partners whereby the Company acquired the exclusive rights in the United States and, in most cases, worldwide rights to a total of thirty-three products for ten years following first commercial sale of each product. The Company will share varying percentages of the profits after, in most cases, recapturing development, legal and certain operating costs, from the sales of the products with the development partners if the products are commercialized. The Company expenses these costs as incurred.
	Commercialization Rights
	In May 2008, the Company entered into a collaborative product development agreement with a Branded product company, whereby the Company has agreed to develop a product for the Brand Company. Under the terms of the agreement, the Brand Company acquired the exclusive worldwide rights to market the product for ten years following approval. The Company will receive a royalty on net sales of the product, dependent upon the achievement of certain goals. In addition, the Company received $750 upon signing which was non-refundable and recorded as revenue in the year it was received and it will receive milestones of up to $13,000 upon the achievement of certain goals. The Brand Company is also required to pay all out of pocket costs related to the project and also made payments to the Company totaling $2,000 for the development of the product, payable at $200 per month commencing in April 2008. In July 2013, an arbitration settlement between the two companies was reached. The Company then terminated the contract; therefore no additional revenues will be recognized.

Asset_Sales

Asset Sales	12 Months Ended
	Sep. 30, 2014
Deferred Revenue Disclosure [Abstract]
Asset Sales	Asset Sales
	On March 28, 2012, the Company entered into an Asset Purchase Agreement (“APA”) with Hikma Pharmaceutical Co. LTD, or Hikma. Under the terms of the agreement, Hikma acquired exclusive U.S. rights to market diclofenac-misoprostol following regulatory approval. The Company received $3,500 upon signing the APA. This amount was included in deferred revenue until FDA approval, since it was otherwise refundable. In addition, the Company was entitled to receive another $1,000 upon regulatory approval, validation batch manufacturing with inventory released for launch, and sufficient launch inventory. Before approval, this approval milestone was to be reduced for each generic competitor that received regulatory approval (excluding an "authorized generic" version of the Brand Product); however, the milestone was not to be reduced to an amount less than $500. The Company was to receive a royalty on Net Profits of the product for a period of ten years from the date of the first commercial sale of the product, with the royalty percentage varying depending upon certain events and competition.
	On June 24, 2013, Hikma filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging that the Company (a) breached the Hikma, APA by failing to refund the purchase price following Hikma's purported termination of the Hikma APA as a result of the Company failing to receive timely ANDA approval, and (b) intentionally failed to disclose alleged manufacturing product defects to Hikma. The Company believed that it did not fail to receive timely ANDA approval and therefore that Hikma was not entitled to (a) terminate the Hikma APA or (b) receive a refund of the purchase price. The Company also believed that it did not intentionally fail to disclose alleged manufacturing product defects to Hikma. If Hikma had prevailed on its claims, the Company could have been required to return the $3,500 purchase price plus interest, as well as other damages. The Company could not estimate the possible loss or range of loss related to the Hikma litigation beyond the $3,500 purchase price.
	On March 14, 2014, the Company received FDA approval of our Abbreviated New Drug Application for diclofenac-misoprostol tablets. The Company had not yet recognized the $3,500 as revenue since it was required to submit additional data to the FDA. In May 2014, under a CBE-30 supplement, the Company submitted additional data to the FDA with respect to manufacturing procedures of the product and achieved final approval in June 2014.
	On June 30, 2014, the Company had recognized the $3,500 purchase price as revenue in Other income as it had received FDA approval and subsequently complied with all FDA requirements. Pursuant to the in-license agreement for diclofenac-misoprostol, the Company estimated amounts due to the licensor.
	On August 8, 2014, the Company settled the lawsuit with Hikma related to the APA. Pursuant to the terms of the settlement the Company retained ownership of diclofenac-misoprostol including the rights to launch and commercialize the Product, and the Company will pay to Hikma a percentage of Net Profits after recovery of certain of the Company's expenses.
	During fiscal year 2010 and 2011, the Company divested another non-core product and received proceeds of $6,500, comprised of $5,500 as a signing milestone which is recorded in deferred revenues and $500 for the initiation of Tech Transfer of which $250 remains in deferred revenues and a second payment of $500 for the completion of the Tech Transfer of which $250 remains in deferred revenues. Under the terms of this agreement, the licensor must obtain all of the following milestones in order for the Company to earn the revenues. These milestones are a) the receipt of an approval letter from the FDA, b) acknowledgment from the FDA that no further clinical studies will be needed and c) an approval letter from the FDA. If these milestones are not met, then the $6,000 in total included in deferred revenue on the balance sheet at September 30, 2014 and September 30, 2013 must be refunded and the product rights are returned to the Company. In addition, the Company may receive additional milestones of up to $3,000 in the future, dependent on the licensor's actively selling the product in an exclusive market position.
	See Note 5 for a summary of Deferred Revenue related to the Asset Sales.

Commitments

Commitments	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments
	At September 30, 2014, the Company has purchase obligations in the amount of $2,319 which represent the contractual commitments under a Contract Manufacturing and Supply Agreement with a supplier. The obligation under the supply agreement is primarily for finished product and research and development.
	The Company leases its office space under a lease agreement that expires on May 31, 2015. Rental expense was $277, $314, and $329, for the years ended September 30, 2014, 2013, and 2012, respectively. The remaining future lease payments under the operating lease are $182 as of September 30, 2014, payable monthly through May 31, 2015.

Arbitration

Arbitration	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Arbitration	Arbitration
	On October 26, 2011, the Company filed a Demand for Arbitration with the American Arbitration Association against a commercial partner that licensed one of its products. Eagle's claims include breach of contract relating to the development of a new formulation of the product and lack of effort to seek and obtain regulatory approval, ultimately impacting the marketing and sale of that new formulation. As a result, Eagle alleged that it had been significantly damaged. A three person arbitration panel was appointed. The trial was completed on January 25, 2013.
	In April 2013, the Company successfully renegotiated the terms of our legal fees to a contingent settlement as opposed to an hourly billing rate. As a result of the renegotiated terms, the Company recognized a $1,993 benefit.
	On July 19, 2013, the American Arbitration Association panel awarded the Company $5,000 for damages plus $24 for apportioned costs related to the arbitration for breach of contract. The Company received the funds in September 2013 and the amount was recorded in the results of operations, net of expenses of $974 in the fourth quarter of fiscal year 2013.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings
	Claims and lawsuits may be filed against the Company from time to time. Although the results of pending claims are always uncertain, the Company believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from such actions.
	In September 2013, the Company filed a New Drug Application under Section 505(b)(2) for EP-3101 (bendamustine RTD) and notified Teva Pharmaceuticals, the holder of Treanda®, the referenced approved drug in our application, of the Company's 505(b)(2) filing and paragraph IV certification. Teva filed a patent infringement lawsuit against the Company in the United States District Court for the District of Delaware on October 21, 2013 to defer the approval of the bendamustine indication. Teva's filing of the lawsuit invoked a 30-month stay of FDA approval of the Company's bendamustine product, which will delay FDA approval until the earlier of the March 2016 expiration of the 30-month stay imposed by the Hatch-Waxman Act, or such time as the district court enters judgment in the Company's favor or otherwise acts to shorten the stay. Moreover, regardless of when the 30-month stay is resolved or expires, the FDA may still be prohibited from approving the Company's 505(b)(2) NDA due to Teva's unexpired orphan drug and pediatric exclusivities for Treanda®. Specifically, Teva has received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the Chronic Lymphocytic Leukemia ("CLL") and indolent B-cell non-Hodgkin's Lymphoma ("NHL") indications, respectively. When a drug, such as Treanda®, has orphan drug exclusivity, the FDA may not approve any other application to market the same drug for the same indication for a period of up to seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. In the United States, pediatric exclusivity adds six months to any existing exclusivity period. If the Company cannot demonstrate that EP-3101 is clinically superior to Treanda®, or qualify under certain other limited exceptions, the Company will not be able to enter the market for the CLL indication until September 2015 (assuming the 30-month stay is resolved by that time) or the NHL indication until May 2016.
	In July 2014, the FDA had granted tentative approval and orphan drug designation to the Company’s New Drug Application for patented Bendamustine Hydrochloride Injection, a ready-to-dilute concentrate solution (“bendamustine RTD”) for the treatment of NHL.
	In September 2014, Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., had moved to dismiss with prejudice its first lawsuit alleging that Eagle’s tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents, U.S. Patent No. 8,445,524. The case was filed in the United States District Court for the District of Delaware in October, 2013.
	Cephalon recently filed a second lawsuit in the District of Delaware alleging that Eagle’s bendamustine product infringes Cephalon’s newly-issued U.S. Patent No. 8,791,270 and that case remains pending.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
	The Company, at times, maintains balances with financial institutions in excess of the FDIC limit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash and cash equivalents, accounts receivable, and accounts payable. The carrying values of these financial instruments approximate their fair values due to their short term maturities.
Short Term Investments	Short Term Investments
	Investments consisted of U.S. Treasury securities that had an original maturity of greater than three months. The Company's investments were classified as Level 1 and available-for-sale and are recorded at fair value, based upon quoted market prices. No gains or losses on investments are realized until the sale occurs or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Fair Value Measurements	Fair Value Measurements
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	•	Level 1: Quoted prices in active markets for identical assets or liabilities.
	•	Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The fair value of interest-bearing cash and cash equivalents and short term investments are classified as Level 1 at September 30, 2014 and September 30, 2013.
	The Company is required by U.S. GAAP to record certain assets and liabilities at fair value on a recurring basis.
	The guidance in ASC 815 required that the Company mark the value of its warrant liability (See Note 6) to market and recognize the change in valuation in its statement of operations each reporting period. Determining the warrant liability to be recorded required the Company to develop estimates to be used in calculating the fair value of the warrant.
	Since these preferred stock warrants did not trade in an active securities market, the Company recognized a warrant liability and estimated the fair value of these warrants using a Probability-Weighted Expected Returns valuation model. Therefore, the warrant liability was considered a Level 3 measurement.
Concentration of Major Customers and Vendors	Concentration of Major Customers and Vendors
	The Company is dependent on commercial partners to market and sell argatroban, from which most of its revenues are currently derived; therefore, the Company's future revenues are highly dependent on these distribution arrangements.
Pre-Launch Inventory	Pre-Launch Inventory
	The Company capitalizes inventory costs associated with certain products prior to regulatory approval and product launch, based on management's judgment of reasonably certain future commercial use and net realizable value, when it is reasonably certain that the pre-launch inventories will be saleable. The determination to capitalize is made once the Company (or its third party development partners) has filed a New Drug Application (an "NDA") that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal hurdles will be cleared. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the drug product being considered, and accordingly, the time frame within which the determination is made varies from product to product. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, or a delay in commercialization, or other potential factors.
Inventory	Inventory
	Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis and consists of finished products. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in value is first recognized. In most instances, inventory is shipped from the Company's vendor directly to the Company's customers.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost. Depreciation is computed over the estimated useful lives of the assets utilizing the straight-line method. Leasehold improvements are being amortized over the shorter of their useful lives or the lease term.
Research and Development Expense	Research and Development Expense
	Costs incurred for research and product development, including costs incurred for technology in the development stage, are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Advance payments for goods or services that will be used for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or services performed.
Deferred Financing Costs	Deferred Financing Costs
	Prior to the initial public offering, costs relating to obtaining Convertible Notes were capitalized and amortized over the term of the related debt using the straight line method.
Deferred IPO Costs	Deferred Initial Public Offering Costs
	Costs incurred of $2,074 related to the initial public offering, consisting primarily of professional fees, were deferred until the completion of the offering at which time such costs, as well as underwriters' fees paid, were netted against proceeds received and reclassified to Additional paid-in capital.
Advertising and Marketing	Advertising and Marketing
	Advertising and marketing costs are expensed as incurred.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock
	The carrying value of redeemable convertible preferred stock was increased by periodic accretions, using the interest method so that the carrying amount would equal the redemption amount at the earliest redemption date.
Accounting for Income Taxes	Accounting for Income Taxes
	The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.
Revenue Recognition	Revenue Recognition
	Product Revenue — The Company recognizes net revenue from Argatroban supplied to its commercial partners and Ryanodex® supplied to the end user, when the following four basic revenue recognition criteria under the related accounting guidance are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Prior to the shipment of manufactured products, the Company conducts initial product release and stability testing in accordance with cGMP. The Company's commercial partners can return the products within contracted specified timeframes if the products do not meet the applicable inspection tests.The Company estimates its return reserves based on its experience with historical return rates. Historically, product returns have not been material. The Company has a no return policy for Ryanodex®.
	Revenues from product sales to end users are recorded net of provisions for estimated chargebacks, rebates, returns (if applicable), prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Eagle, the revenue is deferred to a future period when more information is available to evaluate the impact.
	Royalties — The Company recognizes revenue from royalties based on its commercial partners' net sales of products. Royalties are recognized as earned in accordance with contract terms when they can be reasonably estimated and collectability is reasonably assured. The Company's commercial partners are obligated to report their net product sales and the resulting royalty due to the Company within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial.
	Collaborative licensing and development revenue — The Company recognizes revenue from reimbursements received in connection with feasibility studies and development work for third parties when its contractual services are performed, provided collectability is reasonably assured. Its principal costs under these agreements include its personnel conducting research and development, and its allocated overhead, as the well as research and development performed by outside contractors or consultants.
	The Company recognizes revenues from non-refundable up-front license fees received under collaboration agreements ratably over the performance period as determined under the collaboration agreement (estimated development period in the case of development agreements, and contract period or longest patent life in the case of supply and distribution agreements). If the estimated performance period is subsequently modified, the Company will modify the period over which the upfront license fee is recognized accordingly on a prospective basis. Upon termination of a collaboration agreement, any remaining non-refundable license fees received by the Company, which had been deferred, are generally recognized in full. All such recognized revenues are included in collaborative licensing and development revenue in its statements of operations. The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event, and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the collaboration agreement.
Stock-based Compensation	Stock-Based Compensation
	The Company accounts for stock-based compensation using the fair value provisions of ASC 718, Compensation — Stock Compensation that requires the recognition of compensation expense, using a fair-value based method, for costs related to all stock-based payments including stock options and restricted stock. This topic requires companies to estimate the fair value of the stock-based awards on the date of grant for options issued to employees and directors. The Company uses a Black-Scholes valuation model as the most appropriate valuation method for pricing these options. Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest. There are customary limitations on the sale or transfer of the stock.
	The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions:
		Year Ended September 30,
		2014	2013	2012
	Risk-free interest rate	1.77% - 2.16%	.95% - 2.53%	.82% - 3.23%
	Volatility	53.7%-64.0%	64.00%	34.34%-39.38%
	Expected term (in years)	6.07 - 9.39 years	6.07 - 10.00 years	6.07 - 10.00 years
	Expected dividend yield	0.00%	0.00%	0.00%
	The risk-free rate assumption was based on U.S. Treasury instruments whose term was consistent with the expected term of the stock options. The expected stock price volatility was determined by examining the historical volatilities for industry peers as the Company did not have any trading history for its common stock. Industry peers consist of those companies in the pharmaceutical industry similar in size, stage of life-cycle and financial leverage. The expected term of stock options represents the average of the vesting period and the contractual life of the option for employees and the life of the option for consultants. The expected dividend assumption is based on the Company's history and expectation of future dividend payouts. Changes in the estimated forfeiture rates are reflected prospectively.
Net Loss Per Share	Net Loss Per Share
	Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except that the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debt and other such convertible instruments. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	Total Product Sales and Royalty revenues, and accounts receivables broken down by major customers as a percentage of the total are as follows:
		Year Ended September 30,
		2014			2013		2012
	Net product sales and royalty revenues
	The Medicines Company	45	%		54	%	100	%
	Sandoz, Inc.	53	%		46	%	0	%
	Other	2	%		0	%	0	%
		100	%		100	%	100	%
		September 30,
		2014			2013
	Accounts receivable
	The Medicines Company	75	%		58	%
	Sandoz, Inc.	18	%		40	%
	Other	7	%		2	%
		100	%		100	%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	The fair value of stock options granted to employees, directors, and consultants is estimated using the following assumptions:
		Year Ended September 30,
		2014		2013		2012
	Risk-free interest rate	1.77% - 2.16%		.95% - 2.53%		.82% - 3.23%
	Volatility	53.7%-64.0%		64.00%		34.34%-39.38%
	Expected term (in years)	6.07 - 9.39 years		6.07 - 10.00 years		6.07 - 10.00 years
	Expected dividend yield	0.00%		0.00%		0.00%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The anti-dilutive common shares equivalents outstanding at the years ended September 30, 2014, 2013 and 2012 were as follows:
		Year Ended September 30,
		2014			2013		2012
	Series A	888,099			2,332,059		3,157,154
	Series B	754,191			1,980,429		2,504,197
	Series B-1	554,382			1,455,750		1,501,930
	Series C	654,896			1,719,690		—
	Series C warrants	56,078			147,254		30,971
	Options	963,495			813,529		739,808
	Total	3,871,141			8,448,711		7,934,060

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories consist of the following:
		September 30,
		2014		2013
	Finished products	$	1,294	$	—
		$	1,294	$	—

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment at consist of the following:
		September 30,						Estimated Useful Life (years)
		2014			2013
	Furniture and equipment	$	297		$	297		7
	Office equipment	193			293			3
	Equipment	593			593			7
	Leasehold improvements	41			41			2
		1,124			1,224
	Less accumulated depreciation	(780		)	(822		)
	Property and equipment, net	$	344		$	402

Balance_Sheet_Accounts_Tables

Balance Sheet Accounts (Tables)	12 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following:
		September 30,
		2014		2013
	Prepaid expenses and other current assets
	Prepaid product costs	$	840	$	730
	Prepaid FDA user fee	197		1,023
	Prepaid insurance	345		118
	All other	329		32
	Total Prepaid expenses and other current assets	$	1,711	$	1,903
Schedule of Accrued Expenses	Accrued expenses consist of the following:
		September 30,
		2014		2013
	Accrued expenses
	Royalties due to The Medicines Company	$	4,707	$	1,724
	Royalties due to SciDose	1,050		547
	Accrued research & development	1,498		283
	Accrued professional fees	591		275
	Accrued salary and other compensation	890		170
	Accrued product costs	490		63
	All other	445		68
	Total Accrued expenses	$	9,671	$	3,130
Schedule of Deferred Revenue	Deferred revenue consists of the following:
		September 30,
		2014		2013
	Deferred revenue
	The Medicines Company	$	585	$	520
	Deferred Revenue for ongoing business	585		520
	Hikma Pharmaceuticals, Co. Ltd. (See Note 11)	—		3,500
	Par Pharmaceuticals Companies, Inc.	5,500		5,500
	Par Pharmaceuticals Companies, Inc./Tech Transfer	500		500
	Deferred Revenue from Asset Sales (See Note 11)	6,000		9,500
	Total Deferred revenue	$	6,585	$	10,020

Shares_Subject_to_Redemption_C1

Shares Subject to Redemption b Convertible Preferred Stock Tables (Tables)	12 Months Ended
	Sep. 30, 2014
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount [Abstract]
Schedule of Accrued Dividends not Declared
		September 30,
		2014		2013		2012
	Series A	—		5,722		6,564
	Series B	—		7,111		7,252
	Series B-1	—		2,535		1,569
	Series C	—		567		—
	Total	$	—	$	15,935	$	15,385

Common_Stock_and_StockBased_Co1

Common Stock and Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Recognized Share-based Compensation in Statements of Operations	The Company recognized share-based compensation in its statements of operations for the years ended September 30, 2014, 2013 and 2012 as follows:
		Year Ended September 30,
		2014			2013			2012
	Selling, general and administrative	$	303		$	153		$	281
	Research and development	303			164			121
	Total	$	606		$	317		$	402
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	The following table is a summary of the Company's stock options issued to employees, directors and consultants (amounts in thousands except per share amounts):
		Number of		Weighted			Non-			Exercisable
		Stock		Average			Exercisable
		Option		Exercise
		Shares		Price
	Outstanding at September 30, 2011	657,850		$	5.32		288,605			369,245
	Granted	195,471		$	8.78
	Exercised	—
	Forfeited or expired	(113,513	)
	Outstanding at September 30, 2012	739,808		$	6.22		304,226			435,582
	Granted	194,065		4.42
	Exercised	—
	Forfeited or expired	(120,614	)
	Outstanding at September 30, 2013	813,259		$	5.58		302,603			510,656
	Granted	558,699		11.72
	Exercised	(12,034	)	$	5.34
	Forfeited or expired	(50,931	)
	Outstanding at September 30, 2014	1,308,993		$	8.16		712,901			596,092

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:
		Year Ended September 30,
		2014			2013			2012
	Federal tax benefit at statutory rate	(34.00	)%		(34.00	)%		(34.00	)%
	Non-cash interest and change in fair value of warrants liability	1.07	%		13.82	%		—	%
	State tax benefit, net of Federal benefits	(6.72	)%		(12.95	)%		(3.88	)%
	Research & Development Credit	0.62	%		(5.14	)%		(0.72	)%
	Other	0.06	%		0.22	%		0.07	%
	Net changes in valuation allowance	32.25	%		25.11	%		34.65	%
	Tax benefit	(6.72	)%		(12.94	)%		(3.88	)%
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred tax assets were as follows:
		September 30,
		2014				2013
	Deferred tax assets
	Net operating loss carryforward	$	32,527			$	26,984
	Prepaid research & development expenses	2,354				2,573
	Research & development credit	1,886				2,033
	Advance billings	234				208
	Stock based compensation	944				688
	Accrued bonus	204				—
	Patent costs	70				77
	Intangible assets	34				39
	Fixed assets	—				161
	Accrued vacation pay	54				—
	Returns and allowances	—				24
	Charitable contribution carryforward	80				28
	Other	2				2
	Total deferred tax assets	38,389				32,817
	Deferred tax liabilities
	Prepaid expenses	138				47
	Fixed assets	5				—
	Total deferred tax liabilities	143				47
	Net deferred tax assets	38,246				32,770
	Valuation allowance	$	(38,246	)		$	(32,770	)

Organization_and_Business_Acti1

Organization and Business Activities (Details) (USD $)	1 Months Ended		12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 18, 2014	Feb. 28, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Feb. 18, 2014	Oct. 02, 2012	Mar. 18, 2014
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs			3,450,000
Aggregate net proceeds received from IPO	$46,069
Proceeds from exercise of preferred stock warrants	$21	$21	$21	$0	$0
Issuance of common stock upon exercise of Redeemable Series C preferred stock warrants, shares	1,788	1,788
Total issued common stock			14,032,167	3,048,131
Decrease in number of authorized common shares in connection with IPO			50,000,000	80,000,000
Decrease in number of authorized preferred shares in connection with IPO			1,500,000	0
IPO
Subsidiary, Sale of Stock [Line Items]
Reverse stock split in connection with IPO						0.156
Decrease in number of authorized common shares in connection with IPO						50,000,000
Decrease in number of authorized preferred shares in connection with IPO						1,500,000
Common stock
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock							1,395,226
Common stock | IPO
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs						3,350,000
IPO share price						15
Common stock | Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in connection with initial public offering, net of offering costs								100,000
Preferred stock | IPO
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock						7,487,928
Warrants | IPO
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred shares to common stock						32,286

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Major Customers as a Percentage (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Accounts Receivable
Concentration Risk [Line Items]
Percentage of concentration	100.00%	100.00%
Accounts Receivable | The Medicines Company
Concentration Risk [Line Items]
Percentage of concentration	75.00%	58.00%
Accounts Receivable | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration	18.00%	40.00%
Accounts Receivable | Other
Concentration Risk [Line Items]
Percentage of concentration	7.00%	2.00%
Customer Concentration Risk | Net Revenues
Concentration Risk [Line Items]
Percentage of concentration	100.00%	100.00%	100.00%
Customer Concentration Risk | Net Revenues | The Medicines Company
Concentration Risk [Line Items]
Percentage of concentration	45.00%	54.00%	100.00%
Customer Concentration Risk | Net Revenues | Sandoz, Inc.
Concentration Risk [Line Items]
Percentage of concentration	53.00%	46.00%	0.00%
Customer Concentration Risk | Net Revenues | Other
Concentration Risk [Line Items]
Percentage of concentration	2.00%	0.00%	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Narrative (Details) (USD $)	12 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2014
Short-term Debt [Line Items]
Amortization of deferred financing costs	$0	$96	$19
IPO costs reclassified to Additional Paid In Capital	2,074
Advertising and marketing costs	2,506
Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term	60 days
Convertible Note and Warrant Purchase Agreement | Convertible notes payable
Short-term Debt [Line Items]
Amortization of deferred financing costs	0	96	19
Unamortized deferred financing costs	0	0
Hikma Pharmaceuticals, Co. Ltd. | Asset sales
Short-term Debt [Line Items]
Deferred revenue				$3,500

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Assumption of Stock Options Granted (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest minimum rate	1.77%	0.95%	0.82%
Risk-free interest maximum rate	2.16%	2.53%	3.23%
Volatility minimum	53.70%	64.00%	34.34%
Volatility maximum	64.00%	64.00%	39.38%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 26 days	6 years 0 months 26 days	6 years 0 months 26 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	9 years 4 months 21 days	10 years	10 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Common Shares Equivalents Outstanding (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	3,871,141	8,448,711	7,934,060
Series A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	888,099.18	2,332,059	3,157,154
Series B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	754,190.77	1,980,429	2,504,197
Series B-1
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	554,381.51	1,455,750	1,501,930
Series C
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	654,895.64	1,719,690	0
Series C warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	56,077.55	147,254	30,971
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares equivalents outstanding	963,495	813,529	739,808

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw material - pre launch inventory	$1,294	$0
Inventories	$1,294	$0

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Line Items]
Property and equipment	$1,124	$1,224
Less accumulated depreciation	-780	-822
Property and equipment, net	344	402
Depreciation expense	104	135	240
Assets held for future use, not subject to depreciation	270	270
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	297	297
Estimated Useful Life (years)	7 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	193	293
Estimated Useful Life (years)	3 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	593	593
Estimated Useful Life (years)	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$41	$41
Estimated Useful Life (years)	2 years

Balance_Sheet_Accounts_Prepaid

Balance Sheet Accounts - Prepaid and Other Current Assets (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Prepaid product costs	$840	$730
Prepaid FDA user fee	197	1,023
Prepaid insurance	345	118
All other	329	32
Total Prepaid expenses and other current assets	$1,711	$1,903

Balance_Sheet_Accounts_Accrued

Balance Sheet Accounts - Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Components of Accrued Expenses [Line Items]
Accrued research & development	$1,498	$283
Accrued professional fees	591	275
Accrued salary and other compensation	890	170
Accrued product costs	490	63
Other accrued liabilities	445	68
Total Accrued expenses	9,671	3,130
The Medicines Company
Components of Accrued Expenses [Line Items]
Royalties Due	4,707	1,724
SciDose
Components of Accrued Expenses [Line Items]
Royalties Due	$1,050	$547

Balance_Sheet_Accounts_Deferre

Balance Sheet Accounts - Deferred Revenue (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$6,585	$10,020
Ongoing business
Deferred Revenue Arrangement [Line Items]
Deferred revenue	585	520
Ongoing business | The Medicines Company
Deferred Revenue Arrangement [Line Items]
Deferred revenue	585	520
Asset sales
Deferred Revenue Arrangement [Line Items]
Deferred revenue	6,000	9,500
Asset sales | Hikma Pharmaceuticals, Co. Ltd.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	3,500
Asset sales excluding Tech Transfers | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	5,500	5,500
Tech Transfer | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$500	$500

Notes_Payable_Details

Notes Payable (Details) (USD $)	1 Months Ended		3 Months Ended	12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 18, 2014	Feb. 28, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Oct. 02, 2012	Feb. 18, 2014	Feb. 18, 2014	Sep. 26, 2012	Aug. 02, 2012
Short-term Debt [Line Items]
Warrants liability			$0	$0	$1,707
Expected term of warrants				6 years
Proceeds from exercise of preferred stock warrants	21	21		21	0	0
Issuance of common stock upon exercise of Redeemable Series C preferred stock warrants, shares	1,788	1,788
Change in fair value of warrant liability				573	1,052	0
Debt interest expense			0	0	545	109
Amortization of debt discount				0	1,091	218
Redeemable Convertible Preferred Stock
Short-term Debt [Line Items]
Conversion of stock, shares converted							8,943,447
Common stock
Short-term Debt [Line Items]
Conversion of preferred shares to common stock							1,395,226
Series C Convertible Preferred Stock
Short-term Debt [Line Items]
Conversion of preferred shares to common stock								1,719,693
Convertible Note and Warrant Purchase Agreement
Short-term Debt [Line Items]
Warrants monthly accrual rate											2.00%
Warrants outstanding (in shares)			0	0	944,210					944,210
Warrants liability					1,707			2,280	2,280
Warrants exercise price			1.82	1.82
Change in fair value of warrant liability				573	1,052	0
Amortization of debt discount					545
Convertible Note and Warrant Purchase Agreement | Other income and expense
Short-term Debt [Line Items]
Change in fair value of warrant liability			383		1,052
Convertible Note and Warrant Purchase Agreement | Warrants
Short-term Debt [Line Items]
Fair value assumptions, exercise price			$1.82	$1.82
Fair value assumptions, implied stock price			$1.82	$1.82
Fair value assumptions, expected volatility				64.00%
Fair value assumptions, expected dividend rate				6.00%
Fair value assumptions, risk free interest rate				0.83%
Fair value assumptions, expiration term				6 years
Convertible Note and Warrant Purchase Agreement | Series C Convertible Preferred Stock | Warrants
Short-term Debt [Line Items]
Convertible preferred stock, liquidation preference multiple			2	2
Convertible Note and Warrant Purchase Agreement | Convertible notes payable
Short-term Debt [Line Items]
Convertible Notes issued										9,663
Annual interest rate											6.00%
Conversion price pursuant to conversion terms at maturity date											1.82
Debt instrument, unamortized discount										655
IPO | Series C Preferred Stock Warrants
Short-term Debt [Line Items]
Conversion of preferred shares to common stock									32,286
Probability-Weighted Expected Returns Valuation Model | Convertible Note and Warrant Purchase Agreement
Short-term Debt [Line Items]
Warrants liability										655

Shares_Subject_to_Redemption_C2

Shares Subject to Redemption b Convertible Preferred Stock (Details) (USD $)	12 Months Ended			0 Months Ended				6 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Feb. 18, 2014	Oct. 02, 2012	Mar. 08, 2007	Aug. 11, 2008	Jul. 31, 2011	Apr. 11, 2013	Oct. 03, 2012	Aug. 02, 2012
Temporary Equity [Line Items]
Offering cost	$1	$0	$0
Accumulated dividends on the Preferred Stock	0	15,935	15,385
Preferred stockholder annual dividend rate	6.00%
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued	0	14,948,506				20,237,911
Par value per share of Convertible Preferred Stock	$0.00	$0.00				$0.00
Convertible Preferred Stock original issue price per share						$0.97
Conversion of preferred shares to common stock				2,332,051	825,177
Estimated fair value of convertible preferred stock	0	20,057				19,651
Offering cost						180
Accumulated dividends on the Preferred Stock	0	5,722	6,564	97
The liquidation value of the Preferred Stock	0	20,237
Convertible preferred stock, shares outstanding	0	14,948,506
Conversion of stock, shares converted					5,289,405
Forfeitures of dividends on Convertible Preferred Stock					1,718
Convertible preferred stock, shares authorized	0	14,948,506								14,948,506
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued	0	12,694,561					16,052,343
Par value per share of Convertible Preferred Stock	$0.00	$0.00					$0.00
Convertible Preferred Stock original issue price per share							$1.82
Conversion of preferred shares to common stock				1,980,431	532,832
Estimated fair value of convertible preferred stock	0	30,090					29,215
Offering cost							126
Accumulated dividends on the Preferred Stock	0	7,111	7,252	173
The liquidation value of the Preferred Stock	0	30,216
Convertible preferred stock, shares outstanding	0	12,694,561
Conversion of stock, shares converted					3,357,782
Forfeitures of dividends on Convertible Preferred Stock					1,520
Convertible preferred stock, shares authorized	0	12,694,561								12,694,561
Series B-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued	0	9,331,374						10,177,085
Par value per share of Convertible Preferred Stock	$0.00	$0.00						$0.00
Convertible Preferred Stock original issue price per share								$1.82
Conversion of preferred shares to common stock				1,455,753	46,218
Estimated fair value of convertible preferred stock	0	19,374						17,522
Offering cost								144
Accumulated dividends on the Preferred Stock	0	2,535	1,569	125
The liquidation value of the Preferred Stock	0	19,519
Shares of Series B-1 Preferred Stock in exchange for satisfaction of the principal amount of debt											549,451
Convertible preferred stock, shares outstanding	0	9,331,374	9,627,634
Conversion of stock, shares converted					296,260
Forfeitures of dividends on Convertible Preferred Stock					49
Convertible preferred stock, shares authorized	0	9,331,374								9,331,374
Series C Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued	0	11,023,232							11,023,232
Par value per share of Convertible Preferred Stock	$0.00	$0.00							$0.00
Convertible Preferred Stock original issue price per share									$1.82
Conversion of preferred shares to common stock				1,719,693
Estimated fair value of convertible preferred stock	0	20,462							20,062
Offering cost									167
Accumulated dividends on the Preferred Stock	0	567	0	139
The liquidation value of the Preferred Stock	$0	$20,630
Convertible preferred stock, shares outstanding	0	11,023,232
Convertible preferred stock, shares authorized	0	11,901,336

Common_Stock_and_StockBased_Co2

Common Stock and Stock-Based Compensation - Recognized Share-based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$606	$317	$402
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	303	153	281
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$303	$164	$121

Common_Stock_and_StockBased_Co3

Common Stock and Stock-Based Compensation - Share-based Compensation, Options (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Stock Option Shares Outstanding (in shares)	1,308,993	813,259	739,808	657,850
Weighted Average Exercise Price of Options Outstanding (in usd per share)	$8.16	$5.58	$6.22	$5.32
Non- Exercisable Options Outstanding (in shares)	712,901	302,603	304,226	288,605
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	596,092	510,656	435,582	369,245
Number of Stock Option Shares Granted (in shares)	558,699	194,065	195,471
Weighted Average Exercise Price of Stock Options Granted (in usd per share)	$11.72	$4.42	$8.78
Number of Stock Option Shares Exercised (in shares)	-12,034	0	0
Number of Stock Option Shares Forfeited or expired (in shares)	-50,931	-120,614	-113,513
Weighted Average Exercise Price of Stock Options Exercised (in usd per share)	$5.34

Common_Stock_and_StockBased_Co4

Common Stock and Stock-Based Compensation - Narrative (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, award vesting period	4 years
Number of shares available for grant (in shares)	974,311
Weighted-average grant-date fair value of options granted (in usd per share)	$4.61	$1.73	$3.40
Unrecognized compensation cost	$2,614
Total intrinsic value of options exercised	83	0
Weighted average contractual terms of options outstanding	7 years 6 months	7 years	7 years 6 months
Aggregate pre-tax intrinsic value of options outstanding	$5,880	$179	$1,845
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost expense term	4 years

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]
Minimum state tax	$3	$2	$2
Valuation allowance increase	-5,476
Federal and state net operation loss carryforwards	90,448	29,881
Federal and state research and development tax credit carryforwards	1,827	59
Sale of NOL	25,389	11,029	10,740
Sale of tax credit carryforward	177	95	11
Income tax benefit	$1,295	$899	$781

Income_Taxes_Income_Tax_Reconc

Income Taxes Income Tax Reconciliation (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]
Federal tax benefit at statutory rate	-34.00%	-34.00%	-34.00%
Non-cash interest and change in fair value of warrants liability	1.07%	13.82%	0.00%
State tax benefit, net of Federal benefits	-6.72%	-12.95%	-3.88%
Research & Development Credit	0.62%	-5.14%	-0.72%
Other	0.06%	0.22%	0.07%
Net changes in valuation allowance	32.25%	25.11%	34.65%
Tax benefit	-6.72%	-12.94%	-3.88%

Income_Taxes_Deferred_Income_T

Income Taxes Deferred Income Taxes (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$32,527	$26,984
Prepaid research & development expenses	2,354	2,573
Research & development credit	1,886	2,033
Advance billings	234	208
Stock based compensation	944	688
Accrued Bonuses	204	0
Patent costs	70	77
Intangible assets	34	39
Fixed assets	0	161
Accrued vacation pay	54	0
Returns and allowances	0	24
Charitable contribution carryforward	80	28
Other	2	2
Total deferred tax assets	38,389	32,817
Prepaid expenses	138	47
Fixed assets	5	0
Total deferred tax liabilities	143	47
Net deferred tax assets	38,246	32,770
Valuation allowance	($38,246)	($32,770)

License_Agreements_of_Developm1

License Agreements of Development and Commercialization Rights (Details) (USD $)	1 Months Ended		12 Months Ended
	31-May-08	Apr. 30, 2008	Sep. 30, 2014	Jul. 31, 2013
			product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of products with exclusivity rights			33
Marketing rights, term			10 years
Collaborative product development agreement, non-refundable revenue for signing	$750,000
Cumulative milestones upon achievement of goals	13,000,000
Collaborative product development agreement, payment for product development	2,000,000
Collaborative product development agreement monthly revenue		200,000
Collaborative Arrangement, Product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative product development agreement, term of exclusive marketing rights for partner	10 years
Contract Termination [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Product Development Agreement, Expected Future Receivables				$0

Asset_Sales_Details

Asset Sales (Details) (USD $)	0 Months Ended	24 Months Ended	1 Months Ended
	Mar. 28, 2012	Sep. 30, 2011	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013
Deferred Revenue Arrangement [Line Items]
Cash proceeds due to regulatory	$1,000,000
Milestone reduction limit	500,000
Royalty revenue term	10 years
Divestiture of businesses proceeds		6,500,000
Divestiture of business if milestones unattained				6,000,000	6,000,000
Milestone addition limit				3,000,000
Asset sales | Hikma Pharmaceuticals, Co. Ltd.
Deferred Revenue Arrangement [Line Items]
Deferred revenue			3,500,000
Asset sales excluding Tech Transfers | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue, noncurrent		5,500,000
Initiation of Tech Transfer [Member] | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Divestiture of businesses proceeds		500,000
Deferred revenue, noncurrent		250,000
Completion of Tech Transfer [Member] | Par Pharmaceuticals Companies, Inc.
Deferred Revenue Arrangement [Line Items]
Divestiture of businesses proceeds		500,000
Deferred revenue, noncurrent		$250,000

Commitments_Details

Commitments (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$2,319
Operating leases rent expense	277	314	329
Future operating lease payments	$182

Arbitration_Details

Arbitration (Details) (USD $)	0 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jul. 19, 2013	Sep. 30, 2013
Loss Contingencies [Line Items]
Professional fee benefit		$1,993
Arbitration October 2011
Loss Contingencies [Line Items]
Damages awarded to the Company	5,000
Apportioned costs awarded to the Company	24
Arbitration expense		$974

Legal_Proceedings_Details

Legal Proceedings (Details)	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Lawsuit invoked regulatory stay of approval	30 months
Orphan drug exclusivity, FDA stay of application, maximum period	7 years
Orphan drug exclusivity, FDA stay of application, additional domestic period for pediatric exclusivity	6 months

Uncategorized_Items

Uncategorized Items	7/1/2014 - 9/30/2014
	USD ($)
[us-gaap_InterestPaid]	8,000